In:
Antiviral Therapy, SAGE Publications, Vol. 13, No. 3 ( 2008-04), p. 375-380
Abstract:
The aim of this study was to assess the long-term efficacy and safety of first-line treatment with once-daily saquinavir/ritonavir plus two nucleoside reverse transcriptase inhibitors (NRTIs). Methods A total of 272 antiretroviral-naive patients with a CD4 + T-cell count of 200–350 cells/mm 3 were treated with two NRTIs and saquinavir/ritonavir 1,600/100 mg per day for ≥24 weeks. Patients were followed up every 12 weeks for CD4 + T-cell counts, HIV RNA levels, clinical and laboratory toxicities. Intention-to-treat analyses were used for the first 24 weeks of treatment and as-treated analysis after week 24. Results The median baseline CD4 + T-cell count was 269 cells/mm 3 and HIV RNA was 4.7 log 10 copies/ml. At a median follow-up time of 56 (interquartile range [IQR] 25–113) weeks, 262/272 (96.3%) had HIV RNA 〈 400 copies/ml, with a median HIV RNA decline of -2.89 (IQR 3.31–2.37) log 10 copies/ml ( P 〈 0.001) and a median rise in CD4 + T-cell count of 192 (IQR 117–317) cells ( P 〈 0.001). At weeks 24, 48, 72 and 96, 249/272 (91.5%), 157/164 (95.7%), 113/126 (89.7%) and 84/90 (93.3%) had HIV RNA 〈 400 copies/ml, respectively; at the same time points, 83.8%, 92.7%, 85.7% and 85.6% had HIV RNA 〈 50 copies/ml. Drug-related adverse events were reported in 6.3%. Significant rises in total cholesterol, triglyceride, low-density lipoprotein and high-density lipoprotein were seen. Conclusion First-line highly active antiretroviral therapy with once-daily saquinavir/ritonavir plus two NRTIs showed strong antiviral efficacy.
Type of Medium:
Online Resource
ISSN:
1359-6535
,
2040-2058
DOI:
10.1177/135965350801300302
Language:
English
Publisher:
SAGE Publications
Publication Date:
2008
detail.hit.zdb_id:
2118396-X
SSG:
15,3
Permalink